Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338598 · ClinicalTrials.gov registry record · Phase 2
Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00338598 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 20 participants.
The verdict
NCT00338598, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia. Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also, glycine will improve negative symptoms and cognitive deficits in schizophrenia.
Interventions
- DRUG placebo
- DRUG Glycine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338598
The ClinicalTrials.gov registry entry for NCT00338598 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00338598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338598 about?
NCT00338598 is a clinical study titled "Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism". This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia. Glycine will decrease the rewarding action of ethanol and reduce ethanol...
What is the current status of trial NCT00338598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00338598?
The interventions under investigation include: placebo (DRUG), Glycine (DRUG).
Who is sponsoring clinical trial NCT00338598?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.